Literature DB >> 32575050

Good things come in threes (and sometimes fours): Update on renin-angiotensin-aldosterone system inhibitors and COVID-19.

Kieran L Quinn1, Michael Fralick2, Jonathan S Zipursky3, Nathan M Stall1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32575050      PMCID： PMC7272199          DOI： 10.1503/cmaj.75720

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  5 in total

1.  Renin-angiotensin-aldosterone system inhibitors and COVID-19.

Authors:  Kieran L Quinn; Michael Fralick; Jonathan S Zipursky; Nathan M Stall
Journal:  CMAJ       Date:  2020-04-24       Impact factor: 8.262

2.  Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19.

Authors:  Harmony R Reynolds; Samrachana Adhikari; Claudia Pulgarin; Andrea B Troxel; Eduardo Iturrate; Stephen B Johnson; Anaïs Hausvater; Jonathan D Newman; Jeffrey S Berger; Sripal Bangalore; Stuart D Katz; Glenn I Fishman; Dennis Kunichoff; Yu Chen; Gbenga Ogedegbe; Judith S Hochman
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

3.  Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19.

Authors:  Giuseppe Mancia; Federico Rea; Monica Ludergnani; Giovanni Apolone; Giovanni Corrao
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

4.  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.

Authors:  Mandeep R Mehra; Sapan S Desai; SreyRam Kuy; Timothy D Henry; Amit N Patel
Journal:  N Engl J Med       Date:  2020-05-01       Impact factor: 91.245

5.  Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19).

Authors:  Neil Mehta; Ankur Kalra; Amy S Nowacki; Scott Anjewierden; Zheyi Han; Pavan Bhat; Andres E Carmona-Rubio; Miriam Jacob; Gary W Procop; Susan Harrington; Alex Milinovich; Lars G Svensson; Lara Jehi; James B Young; Mina K Chung
Journal:  JAMA Cardiol       Date:  2020-09-01       Impact factor: 14.676
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.